David  Lebwohl net worth and biography

David Lebwohl Biography and Net Worth

Dr. David Lebwohl’s career spans three decades in the biopharmaceutical industry, successfully bringing novel medicines through all phases of clinical trials and global regulatory approvals. During his career, he has overseen multiple full-scale development programs with more than 200 clinical studies across myriad indications.

Before Intellia, David was chief medical officer at Semma, Therapeutics Inc., a subsidiary of Vertex Pharmaceuticals Inc., where he was leading the company’s regenerative medicine efforts using stem-cell-derived pancreatic islets to cure type I diabetes. Prior to his role at Semma Therapeutics, David held numerous senior-level positions leading drug development at the global healthcare company, Novartis Pharmaceuticals Inc. There, he was most recently senior vice president and franchise global program head, CAR-T, Promacta and SEG101 Global Program Teams, responsible for the development of the breakthrough therapy Kymriah® (tisagenlecleucel), approved for the treatment of B-cell acute lymphoblastic leukemia and diffuse large B cell lymphoma. During his time at Novartis, David was responsible for numerous oncology drug development programs. Under his leadership, the blockbuster drug, Afinitor® (everolimus), was approved for five indications, including metastatic breast, neuroendocrine and kidney cancer and a rare genetic disease, tuberous sclerosis. Prior to working at Novartis, David spent five years at Bristol Myers Squibb Inc., where he led oncology development teams at the company’s Pharmaceutical Research Institute.

He is a well-recognized medical oncologist, with certifications in hematology and internal medicine. David received an undergraduate degree in Biochemical Sciences from Harvard College and an M.D. from the Yale University School of Medicine. He completed his fellowship training at Memorial Sloan Kettering Cancer Center and his residency in Internal Medicine at Brigham and Women’s Hospital in Boston. David has authored more than 50 peer-reviewed publications and is a member of the American Society of Clinical Oncology.

What is David Lebwohl's net worth?

The estimated net worth of David Lebwohl is at least $1.21 million as of January 3rd, 2024. Dr. Lebwohl owns 54,372 shares of Intellia Therapeutics stock worth more than $1,205,971 as of April 23rd. This net worth approximation does not reflect any other investments that Dr. Lebwohl may own. Additionally, Dr. Lebwohl receives a salary of $671,420.00 as EVP at Intellia Therapeutics. Learn More about David Lebwohl's net worth.

How old is David Lebwohl?

Dr. Lebwohl is currently 69 years old. There are 8 older executives and no younger executives at Intellia Therapeutics. Learn More on David Lebwohl's age.

What is David Lebwohl's salary?

As the EVP of Intellia Therapeutics, Inc., Dr. Lebwohl earns $671,420.00 per year. There are 3 executives that earn more than Dr. Lebwohl. The highest earning executive at Intellia Therapeutics is Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board, who commands a salary of $1,380,000.00 per year. Learn More on David Lebwohl's salary.

How do I contact David Lebwohl?

The corporate mailing address for Dr. Lebwohl and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]. Learn More on David Lebwohl's contact information.

Has David Lebwohl been buying or selling shares of Intellia Therapeutics?

David Lebwohl has not been actively trading shares of Intellia Therapeutics over the course of the past ninety days. Most recently, David Lebwohl sold 5,843 shares of the business's stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $29.46, for a transaction totalling $172,134.78. Following the completion of the sale, the executive vice president now directly owns 54,372 shares of the company's stock, valued at $1,601,799.12. Learn More on David Lebwohl's trading history.

Who are Intellia Therapeutics' active insiders?

Intellia Therapeutics' insider roster includes Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Jean-Francois Formela (Director), Glenn Goddard (CFO), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.

Are insiders buying or selling shares of Intellia Therapeutics?

In the last year, insiders at the sold shares 10 times. They sold a total of 42,760 shares worth more than $1,368,462.19. The most recent insider tranaction occured on March, 4th when EVP James Basta sold 2,297 shares worth more than $75,778.03. Insiders at Intellia Therapeutics own 3.0% of the company. Learn More about insider trades at Intellia Therapeutics.

Information on this page was last updated on 3/4/2024.

David Lebwohl Insider Trading History at Intellia Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2024Sell5,843$29.46$172,134.7854,372View SEC Filing Icon  
11/5/2021Sell2,400$132.72$318,528.00View SEC Filing Icon  
10/14/2021Sell2,400$128.44$308,256.00View SEC Filing Icon  
9/21/2021Sell2,400$149.81$359,544.00View SEC Filing Icon  
8/9/2021Sell2,400$164.05$393,720.003,191View SEC Filing Icon  
See Full Table

David Lebwohl Buying and Selling Activity at Intellia Therapeutics

This chart shows David Lebwohl's buying and selling at Intellia Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intellia Therapeutics Company Overview

Intellia Therapeutics logo
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $22.18
Low: $21.65
High: $22.85

50 Day Range

MA: $27.05
Low: $21.32
High: $32.80

2 Week Range

Now: $22.18
Low: $20.78
High: $47.48


319,757 shs

Average Volume

1,495,877 shs

Market Capitalization

$2.14 billion

P/E Ratio


Dividend Yield